Design Therapeutics Inc
$ 10.65
-1.02%
05 Jun - close price
- Market Cap 665,167,000 USD
- Current Price $ 10.65
- High / Low $ 10.92 / 10.51
- Stock P/E N/A
- Book Value 3.49
- EPS -1.20
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.31 %
- 52 Week High 17.25
- 52 Week Low 3.33
About
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Analyst Target Price
$21.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.29 | -0.27 | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 |
| Estimated EPS | -0.35 | -0.33 | -0.3367 | -0.2967 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.41 | -0.4 |
| Surprise | 0.06 | 0.06 | 0.0367 | -0.0433 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.13 | 0.04 |
| Surprise Percentage | 17.1429% | 18.1818% | 10.8999% | -14.5939% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 31.7073% | 10% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-06-04 18:10:57
Design Therapeutics, Inc. (DSGN) has reported positive early clinical data for its novel small molecule genomic medicine platform in treating Friedreich's ataxia. The data showed significant biomarker and clinical improvements at a 1 mg/kg dose, supporting the advancement of ongoing studies towards registrational development. A major update regarding these studies is anticipated in Q4.
2026-05-29 22:39:19
This page provides a stock chart for DESIGN THERAPEUTICS INC (NASDAQ:DSGN). It displays the company's current stock price, which closed at 10.44 USD with a slight decrease of 0.38%. The page also offers various tools and data for stock analysis, including daily, weekly, and monthly charts.
2026-05-29 18:09:15
Design Therapeutics (DSGN) shares saw a significant jump following the announcement of encouraging early data from its Phase 1 clinical trial of DT-216 for Friedreich ataxia. The company reported that DT-216 showed dose-dependent increases in frataxin levels and was well-tolerated, suggesting potential as a treatment for this rare neurological disorder.
2026-05-29 09:09:16
Piper Sandler analyst Yasmeen Rahimi has reaffirmed a Buy rating on Design Therapeutics (DSGN) and set a price target of $20.00. Rahimi is a 5-star analyst with a strong track record. Design Therapeutics currently holds an analyst consensus of Strong Buy with a price target of $19.60, despite reporting a quarterly GAAP net loss of $17.64 million.
2026-05-28 12:10:29
Design Therapeutics, a clinical-stage biotechnology company, announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The company is developing GeneTAC® small molecules for various degenerative genetic diseases, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. A live webcast of the event will be available on the company's investor relations website.
2026-05-28 12:10:28
Design Therapeutics (Nasdaq: DSGN) is scheduled to participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York. A live webcast and 30-day archive will be available on the company's website. The announcement highlights an ongoing pattern of routine investor outreach by Design Therapeutics as it continues to advance its GeneTAC® gene targeted chimera small molecule programs for serious degenerative genetic diseases.
